אודות פרק זה
Prof Amrita Krishnan of the City of Hope National Medical Center, Los Angeles, USA "Ultimately, if you really want to 'win the game,' you have to cure the HIV and cure the lymphoma," Prof Krishnan tells ecancertv at ASH 2014, describing her work on modifying haematopoietic progenitor cells with gene therapy to engineer resistance to HIV.
The engineered stem cells can then be used alongside other stem cell transplants aimed at treating the lymphoma, creating a two-pronged approach to treating HIV-associated lymphoma.
The engineered stem cells can then be used alongside other stem cell transplants aimed at treating the lymphoma, creating a two-pronged approach to treating HIV-associated lymphoma.
אנגלית
ארצות הברית
תעתיק 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
פרקים אחרים בפודקאסט הזה
Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA talks to ecancertv at ASH 2014 about the use of T cell therapy for children with aggressive leukaemia.
Prof Burnett (Head of Haematology Department of Medical Genetics, Cardiff, Wales) and Prof Amadori (Tor Vergata University Hospital, Rome, Italy) review the data and opinions arising from ASH 2014 about the treatment of acute myeloid leukaemia (AML) for ecancertv.
They debate the use of intensifi…
Prof Marivi Mateos of the University Hospital of Salamanca, Salamanca, Spain speaks to ecancertv at ASH 2014 about the results of a phase I study on the use of daratumumab, an anti-CD38 antibody, in combination with standard approaches to treat relapsed multiple myeloma.
Prof Gribben (Queen Mary University London, London, UK) and Prof Stilgenbauer (Universitätsklinikum Ulm, Ulm, Germany) review the data and opinions arising from ASH 2014 about the treatment of chronic lymphocytic leukaemia (CLL) for ecancertv.
The experts offer a comprehensive analysis of the cur…
Prof Keith Stewart of the Mayo Clinic, Scottsdale, USA talks to ecancertv at ASH 2014 about the phase III ASPIRE study looking at the use of carfilzomib in multiple myeloma.
“By adding carfilzomib to the gold standard in multiple myeloma therapy, we are observing an unprecedented duration of remi…
הצהרה: הפודקאסט והגרפיקה המוטבעים בדף זה הם מ-ecancertv, שהוא רכושו של בעליו ואינו קשור או מאושר על ידי Listen Notes, Inc.
